Impact of Timing of Premedication on Mucosal Visibility During Endoscopy
The trial, sponsored by the Asian Institute of Gastroenterology, investigates the impact of premedication timing on mucosal visibility during upper gastrointestinal endoscopy. Given the increasing prevalence of gastrointestinal disorders and the critical role of early detection in improving patient outcomes, this study addresses a significant clinical need. The findings could enhance procedural efficiency and diagnostic accuracy, potentially leading to broader adoption of simethicone and NAC in endoscopic practices. The market for gastrointestinal endoscopy is substantial, with ongoing advancements in imaging technologies. Successful outcomes may position the combination of simethicone and NAC as a standard premedication protocol, influencing competitive dynamics in the endoscopy market and attracting interest from pharmaceutical companies focused on gastrointestinal therapeutics.
Indication: Endoscopy, Digestive System
Modality: small molecule
Target: Mucosal visibility enhancement during endoscopy through the use of simethicone and N-acetylcysteine as premedication agents.
Sponsor: Asian Institute of Gastroenterology, India
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Mucosal visibility enhancement during endoscopy through the use of simethicone and N-acetylcysteine as premedication agents.
View original source fields
Condition raw: Endoscopy, Digestive System
Condition normalized: Endoscopy, Digestive System
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Mucosal visibility enhancement during endoscopy through the use of simethicone and N-acetylcysteine as premedication agents.
Target normalized: Mucosal visibility enhancement during endoscopy through the use of simethicone and N-acetylcysteine as premedication agents.